Related Experiment Video
Updated: Mar 27, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Open innovation in early drug discovery: roadmaps and roadblocks
Melvin Reichman1, Peter B Simpson2
1Lankenau Institute for Medical Research, Chemical Genomics Center, 100 Lancaster Ave, Wynnewood, PA, USA.
Abstract:
Open innovation in pharmaceutical R&D evolved from a triple helix of convergent paradigm shifts in academic, industrial and government research sectors. The birth of the biotechnology sector catalyzed shifts in location dynamics that led to the first wave of open innovation in pharmaceutical R&D between big pharma and startup companies. The National Institutes of Health (NIH) Roadmap was a crucial inflection point that set the stage for a new wave of open innovation models between pharmaceutical companies and universities that have the potential to transform the pharmaceutical R&D landscape. We highlight the attributes of leading protected open innovation models that foster the sharing of proprietary small molecule collections by lowering the risk of premature escape of intellectual property, particularly structure-activity data.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacogenomics: Identification of New Drug Targets
In Vitro Drug Release Testing: Overview, Development and Validation

